Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company.

Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment ...

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...

Pfizer’s revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it’s faced a drop in that demand and losses of exclusivity ...

Recon: Pfizer to boost US vaccine deliveries as EU secures more doses; Tango to go public in $353M SPAC deal Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...

Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...

Pfizer (PFE) shares fell in the premarket on Tuesday after the company reaffirmed its full-year outlook, indicating a revenue contraction for 2026 amid a nearly $1.5B impact attributed to some of its ...